학술논문
Phase II study investigating the efficacy and safety of glesatinib (MGCD265) in patients with advanced NSCLC containing MET activating alterations
Document Type
Article
Author
Source
In: Lung Cancer . (Lung Cancer, April 2024, 190)
Subject
Language
English
ISSN
18728332
01695002
01695002